从“癌毒–络脉”理论探讨中西医结合调控肠癌微环境的临床与机制进展
From the “Cancer Toxin-Collateral” Theory: Clinical and Mechanistic Advances of Integrated Chinese and Western Medicine in Regulating the Colorectal Cancer Microenvironment
DOI: 10.12677/tcm.2026.1511638, PDF,   
作者: 何宇慈, 张鹤柳:黑龙江中医药大学研究生院,黑龙江 哈尔滨;杨 楠:秦安县中医医院脑病科,甘肃 天水;李 雨*:黑龙江中医药大学附属第一医院肿瘤三科,黑龙江 哈尔滨
关键词: 肠癌;肿瘤微环境;癌毒–络脉;中西医结合;Colorectal Cancer; Tumor Microenvironment; Cancer Toxin-Collateral; Integrated Chinese and Western Medicine
摘要: 肠癌作为全球发病率和死亡率较高的恶性肿瘤,严重威胁人类健康。现代肿瘤微环境研究证实,低氧条件下HIF-1α的病理性高表达及其驱动的VEGF促血管生成级联反应,与中医“毒深陷络”理论在分子层面高度契合。HIF-1α作为低氧微环境中的核心转录调节因子,通过激活HIF-1α/VEGF等信号通路,促进大肠癌细胞增殖、侵袭、转移及血管生成。肿瘤外泌体作为癌毒的“微观载体”,通过递送miR-21、miR-210等miRNA远程调控血管内皮细胞功能,进一步印证了“毒邪深伏、暗中耗损络脉”的微观实质。临床上,中西医结合治疗大肠癌以“宏观破瘀通络,微观抑靶阻管”为核心策略,在化疗减毒增效、靶向/免疫治疗协同增效及维持治疗期防复发转移三个维度展现出独特优势。本文系统梳理“癌毒–络脉”理论指导下中西医结合调控大肠癌微环境的理论基础及临床研究进展,以期为大肠癌的中西医结合精准治疗提供理论依据与实践参考。
Abstract: Colorectal cancer, as a malignant tumor with high global incidence and mortality, poses a serious threat to human health. Modern tumor microenvironment research has confirmed that the pathological overexpression of HIF-1α under hypoxic conditions and its driven VEGF-mediated pro-angiogenic cascade are highly consistent at the molecular level with the traditional Chinese medicine theory of “deep-lying toxin in the collaterals.” As a core transcriptional regulator in the hypoxic microenvironment, HIF-1α promotes the proliferation, invasion, metastasis, and angiogenesis of colorectal cancer cells by activating signaling pathways such as HIF-1α/VEGF. Tumor exosomes, as “microscopic carriers” of cancer toxin, remotely regulate vascular endothelial cell function by delivering miRNAs such as miR-21 and miR-210, further corroborating the microscopic essence of “toxin pathogen hidden deep and secretly depleting the collaterals.” Clinically, integrated Chinese and Western medicine in the treatment of colorectal cancer takes “macro-level breaking blood stasis and dredging collaterals, micro-level inhibiting targets and blocking angiogenesis” as its core strategy, demonstrating unique advantages in three dimensions: reducing toxicity and enhancing the efficacy of chemotherapy, synergistic enhancement with targeted therapy/immunotherapy, and prevention of recurrence and metastasis during maintenance therapy. This article systematically reviews the theoretical basis and clinical research progress of integrated Chinese and Western medicine in regulating the colorectal cancer microenvironment under the guidance of the “cancer toxin-collateral” theory, aiming to provide a theoretical basis and practical reference for precision integrated Chinese and Western medicine treatment of colorectal cancer.
文章引用:何宇慈, 杨楠, 张鹤柳, 李雨. 从“癌毒–络脉”理论探讨中西医结合调控肠癌微环境的临床与机制进展[J]. 中医学, 2026, 15(11): 177-184. https://doi.org/10.12677/tcm.2026.1511638

参考文献

[1] 丁璐璐, 徐源佑, 陈永胜, 等. 全球结直肠癌流行现状与人类发展指数关系分析[J]. 中国肿瘤, 2025, 34(8): 611-617.
[2] 王裕新, 潘凯枫, 李文庆. 2022全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2024, 10(3): 1-16.
[3] 黄金龙, 路平, 梁新军, 等. 免疫联合靶向治疗在MSS/pMMR型晚期结直肠癌中的研究进展[J]. 肿瘤防治研究, 2026, 53(6): 492-498.
[4] 赖桂花, 王菲, 周芳, 等. 差异视角下中西医治疗肿瘤的协同优势[J]. 中医药临床杂志, 2022, 34(4): 599-603.
[5] 吴万垠. 中医药在恶性肿瘤治疗中的“替代”与“补充”作用[J]. 中国中西医结合杂志, 2011, 31(1): 111-114.
[6] 张楠, 孙维义, 任伟东, 等. 黄芪多糖通过调控CSF1/STING-TBK1信号通路抑制结直肠癌CT-26细胞移植瘤小鼠肿瘤组织中M2型巨噬细胞的极化[J]. 肿瘤, 2025, 45(10): 797-811.
[7] 杨丽, 郭栴子, 杨小蒨, 等. 从“痰瘀互结”理论谈“炎-癌转化” [J]. 河北中医, 2020, 42(12): 1887-1889.
[8] 马澳伦, 宁玲, 李青, 等. 基于“虚痰瘀毒”理论的溃疡性结肠炎“炎癌转化”中医药防治探讨[J]. 实用中医内科杂志, 2026, 40(5): 16-19+143.
[9] 温丹婷, 周慧萍. 基于癌毒理论对肿瘤微环境的中医认识[J]. 实用医学杂志, 2023, 39(19): 2556-2560.
[10] 何伟. 活血化瘀中药重塑肿瘤微环境[J]. 中医学报, 2024, 39(6): 1188-1194.
[11] 王瑞婷, 申兴斌, 刘云霞. 免疫监视与肿瘤免疫逃逸[J]. 承德医学院学报, 2001, 18(4): 327-329.
[12] 胡先华. 肿瘤免疫逃逸相关分子及其机制研究进展[J]. 中国医药科学, 2023, 13(8): 36-38+90.
[13] 高桂珍, 郭维娜, 杨学军, 等. 肿瘤免疫逃逸机制及中药干预策略研究进展[J]. 中医药通报, 2025, 24(12): 52-57.
[14] 孟令飞, 朱超伦, 赵子旭, 等. 从“痰瘀窠囊”探讨溃疡性结肠炎“炎癌转化”的动态演变机制与治疗思路[J]. 山东中医杂志, 2026, 45(7): 698-703.
[15] 刘熔, 黄春田, 程新月, 等. 中医药调控TNF通路抑制消化系统炎症-癌变的研究进展[J/OL]. 天然产物研究与开发: 1-20.
https://link.cnki.net/urlid/51.1335.Q.20260324.0950.002, 2026-07-27.
[16] 朱俊韦, 刘晓丽, 杨浩. 乏氧微环境对肿瘤发生发展的作用和分子影像诊疗策略[J/OL]. 生命科学: 1-24.
https://link.cnki.net/urlid/31.1600.Q.20260707.1736.002, 2026-08-02.
[17] 吴学平, 李志宏, 杨玲, 等. 缺氧诱导因子1α和血管内皮生长因子在1型糖尿病大鼠胃组织中表达及意义的研究[J]. 中国糖尿病杂志, 2019, 27(12): 927-933.
[18] 黑玉, 王新, 杨学斌, 等. 肿瘤神经-血管网络结构、功能与治疗新靶点研究进展[J]. 实用肿瘤杂志, 2026, 41(2): 193-198.
[19] Lin, Y., Wu, Y., Ma, J., Fang, L., Liu, B. and Meng, S. (2025) PM2.5 Promotes Non-Small Cell Lung Cancer Tumorigenesis by miR-21-5p Targeting PDE4DIP Accumulated. Translational Cancer Research, 14, 7580-7597.
https://doi.org/10.21037/tcr-2025-626
[20] 张曦, 潘传芳, 胡兵, 等. 中医药对大肠癌血管生成的作用[J]. 中华中医药学刊, 2017, 35(12): 3043-3045.
[21] 王静, 唐泊文, 宋囡, 等. 健脾益气法治疗结直肠癌研究进展[J]. 陕西中医, 2025, 46(3): 420-423.
[22] 汪舒云, 谢曼丽, 孙可向, 等. 参苓白术散对大肠癌移植瘤模型小鼠化学疗法后肠道黏膜屏障的影响[J]. 上海中医药杂志, 2023, 57(4): 57-64.
[23] 李佳, 王文海, 曾宝珠. 肠益煎对大肠癌化疗患者增效减毒作用的临床研究[J]. 时珍国医国药, 2015, 26(3): 638-640.
[24] 莫荔荔, 彭卓嵛, 吴泽铃, 等. 健脾益气法治疗晚期大肠癌的Meta分析[J]. 湖南中医杂志, 2016, 32(12): 138-140.
[25] 葛玲玲. 健脾扶正消积方对CapeOX方案治疗晚期大肠癌减毒作用的临床研究[D]: [硕士学位论文]. 济南: 山东中医药大学, 2019.
[26] 梅灏, 李思旋. 加味四逆异功散治疗晚期大肠癌湿热瘀毒证疗效观察[J]. 山西中医, 2025, 41(3): 29-31.
[27] 刘超峰, 石龙国, 邢冰. 黄芪多糖通过重塑免疫微环境增强程序性死亡受体1抑制剂抗结直肠癌作用的机制研究[J]. 肿瘤基础与临床, 2025, 38(2): 157-161.
[28] Wu, J., Shao, C., Dong, Y., Meng, J., Zhang, H., Lu, L., Lin, L. and Fang, C. (2025) Qu-Yu-Jie-Du Decoction Maintenance Therapy Improves Postoperative Survival in Metastatic Colorectal Cancer: A Single-Center Randomized Trial with 36-Month Follow-Up. Phytomedicine, 146, Article 157143.
[29] 王鄂明, 符克燕, 齐若谷. 四君子汤联合肠内营养对结肠癌手术免疫功能及血清IL-2、IL-6水平的影响[J]. 实用中医内科杂志, 2021, 35(1): 66-69.
[30] 徐燕茹, 陶李蕙苹, 钱景阳, 等. 仙连解毒方通过调控血管生成抗结直肠癌复发的疗效机制[J]. 中国实验方剂学杂志, 2025, 31(6): 79-87.